Skip to main content
Equibles
FDMT logo

FDMT · 4D Molecular Therapeutics, Inc.

Track FDMT — free

Use FDMT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about FDMT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$16.10 -0.66 (-3.94%) At close · Aug 20
Market Cap
$1.20B
Shares
72.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.10 Open$16.50 Day$15.63–16.71 52W close$6.14–16.76 Avg vol 30d852K Short int12.0M · 16.7% float · 17.7d Short vol38% Last earningsAug 8, 2024 DataDec 2020–Aug 2026 Filing10-Q · Aug 13

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +63%
above
Price vs 50-day avg +42%
above
RSI (14) 76
overbought
MACD trend Positive
52-week position 94%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +55%
trailing
6-month return +67%
trailing
YTD return +115%
this year
Relative strength +56%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.68% of float · ▲ +5.9% MoM · 17.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Squeeze score 100
high risk · 0–100
Fundamentals
Strong
Revenue growth +230195%
Y/Y
EPS growth +19%
Y/Y
Free cash flow $-109.6M
Balance sheet $60.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −41%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+63% Bullish
Price vs 50-day avg
+42% Bullish
RSI (14)
76 Bearish
MACD trend
Positive Bullish
52-week position
94% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.68% of float · ▲ +5.9% MoM · 17.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $16 · 94% Range high $17
vs 200-day avg +63% vs 50-day avg +42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $458M Q1 2026 —
First tranche of CF Foundation equity investment received $7.5M full year 2025 —
Gross proceeds from at-the-market offering $10M full year 2025 —
Gross proceeds from November 2025 equity offering $100M full year 2025 —
Net proceeds from November 2025 equity offering $93M full year 2025 —
Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials 480 full year 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FDMT
4D Molecular Therapeutics, Inc.
this stock
$1.20B +114.7% +230194.6% — 16.7%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
159
% held
81.1%
Net QoQ
+7.7M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
167
View
Short & Settlement
Short Interest Rising
Shares short
12.0M
Days to cover
17.7d
Change
+675.0K sh
View
Short Volume
Short vol %
38%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$15.1K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
35.6%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$85.2M
Net income (FY)
$-140.1M
EPS diluted
$-2.42
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
17
View
Proposed Sales
Value
$79.7K
Shares
6.5K
Filed
Aug 17, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View

Performance

5D 20D 120D MTD YTD
FDMT +38.2% +55.1% +66.7% +58.2% +114.7%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +40.2% +51.8% +55.5% +56.1% +102.8%
Key facts CIK 1650648 CUSIP 35104E100 13F (30d) 149 filings 149 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)